Editors-in-Chief

Charles B. Simone II, MD, FASTRO, FACRO

New York Proton Center, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA

Charles B. Simone, II, MD, FACRO is Research Professor and Chief Medical Officer of the New York Proton Center and Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy, reirradiation, and stereotactic body radiation therapy, and in the development of innovative clinical trial strategies in thoracic oncology.

Prior to coming to NYPC, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at University of Pennsylvania and residency in radiation oncology at the National Cancer Institute (NCI), NIH, where he served as chief resident.

Dr. Simone is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who has published >600 scientific articles and chapters, given >525 scientific lectures to national/international audiences, and is the national Principal Investigator or Co-Chair of 8 NIH-funded cooperative group trials (5 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time Association of Residents in Radiation Oncology Educator of the Year Award winner. Dr. Simone is the Proton Collaborative Group (PCG) Board President. He Chairs the American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee, ASTRO Blue Ribbon Lung Panel, NRG Oncology Particle Therapy Work Group, PCG Lung Committee, American Radium Society (ARS) Appropriate Use Criteria Thoracic Committee, Particle Therapy Co-Operative Group (PTCOG) Thoracic Subcommittee, American College of Radiation Oncology (ACRO) Scientific Program Committee, NCI/Radiosurgery Society GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group, Varian FlashForward Consortium Scientific Committee, and Varian Proton Connect Users Group. He is Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Frontiers in Oncology, Translational Lung Cancer Research, Cancers, Journal of Thoracic Disease, Annals of Translational Medicine, Therapeutic Radiology and Oncology, Shanghai Chest, Journal of Xiangya Medicine, and AME Medical Journal.

Zhi-hua Zhu, MD, PhD

State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Zhi-hua Zhu, MD, PhD, is an associate professor at the State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University. Dr. Zhu received his M.D. degree and then trained as a postdoctoral fellow at Sun Yat-sen University. Dr. Zhu has actively been engaged in the pre-clinical and clinical studies on chest tumors including lung cancer, esophageal carcinoma, and breast cancer, with special interests in the palliative treatment of tumors and the individualized treatment of lung cancers. Dr. Zhu has participated in the National 863 key Program on ‘Molecular Typing and Individualized Treatment of Lung Cancer and Esophageal Carcinoma’. Furthermore, Dr. Zhu is the responsible person for a number of research projects supported by National Natural Science Fund, Ministry of Human Resources, and many other State- and province-level institutions. He served as a fellow or visiting scholar in the United States in 2009 and in France and Germany in 2010. Dr. Zhu has published articles in Journal of Clinical Oncology (Zhu ZH, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol. 2009;27:1091-9), Journal of Cancer Research and Clinical Oncology, World Journal of Gastroenterology, Medical Oncology, and many other peer-reviewed journals. Dr. Zhu is a member of the editorial committee of Journal of Thoracic Disease and an expert evaluator for Research Fund for the Doctoral Program of Higher Education of China. He won the ‘Ding Ying Science and Technology Award’ issued by the Province of Guangdong in 2010.